Cancer Breast clinical trials

Explore recruiting cancer breast clinical trials.

Recruiting cancer breast studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cancer Breast trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK 009)

Hungary, Ireland, Spain, France, Germany, Poland

Phase II and Phase III (Integrated) EU CTIS Study details

A multi-center, open-label Phase 1/2 study to evaluate the safety, efficacy, PK and PD of ONA-255 in study participants with advanced cancer

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

SPECT/CT imaging of FPI-2505 in patients with solid tumours; a phase 0 molecular imaging basket trial (SCOPE-study).

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.

Spain, Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

Sweden, Norway, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Cancer Breast trials by city

Cancer Breast in Toronto Cancer Breast in Vancouver Cancer Breast in Montreal Cancer Breast in Calgary Cancer Breast in Edmonton Cancer Breast in Ottawa Cancer Breast in Winnipeg Cancer Breast in Quebec City Cancer Breast in Hamilton Cancer Breast in Kitchener Cancer Breast in London Cancer Breast in Halifax Cancer Breast in New York Cancer Breast in Los Angeles Cancer Breast in Chicago Cancer Breast in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease